Neurocrine Biosciences | NBIX - Trade Creditors



Neurocrine Biosciences reported 104.6M in Trade Creditors for its fiscal quarter ending in June of 2025.


Trade Creditors Change Date
AbbVie 2.94B 2.66B Dec/2024
Acadia Pharmaceuticals USD 20.1M 2M Jun/2025
Agios Pharmaceuticals USD 17.53M 3.81M Jun/2025
ALKERMES USD 99.21M 39.37M Jun/2025
Alnylam Pharmaceuticals USD 102.39M 4.99M Jun/2025
Amgen USD 18.03B 15.63B Jun/2025
Biogen USD 408.4M 16.9M Jun/2025
BioMarin Pharmaceutical 684.25M 390.5M Jun/2025
Cytokinetics USD 68.54M 54.6M Jun/2025
Dynavax Technologies USD 2.7M 1.63M Jun/2025
Exelixis USD 25.82M 17.02M Jul/2025
Gilead Sciences USD 582M 155M Jun/2025
Halozyme Therapeutics USD 18.69M 1.38M Jun/2025
Incyte USD 1.41B 1.21B Jun/2025
Ionis Pharmaceuticals USD 22.8M 5.34M Jun/2025
Neurocrine Biosciences 104.6M 5.4M Jun/2025
Pfizer USD 5.17B 74M Jun/2025
Prothena USD 12.2M 4.43M Jun/2025
Regeneron Pharmaceuticals USD 723.9M 18.4M Jun/2025
Repligen USD 26.94M 5.2M Mar/2025
Sarepta Therapeutics USD 136.7M 19.4M Jun/2025
Teva Pharmaceutical Industries USD 2.5B 208M Jun/2025
Ultragenyx Pharmaceutical USD 34.24M 13.21M Jun/2025
Vertex Pharmaceuticals USD 3.71B 3.27B Jun/2025